Terumo Corporation · TSE:4543
Terumo — Investor Presentation (December 2016)
22 slides from Terumo's investor presentation, Dec 12, 2016
Slide 1: General Hospital Company
4 General Shoji Hatano President, Hospital General Hospital Company Company © Terumo Corporation
Slide 2: Business Overview: General Hospital Company
Business Overview: General Hospital Company FY14-15 FY15 Sales Growth Major products General • Infusion system Hospital 78 B JPY -1.1% Products • Infusion pump General • Infusion solution Hospital D&D 58 B JPY -0.3% • Prefilled syringes Company (B2B: 15 B JPY ) DM and • Blood glucose Consumer 25 B J
Slide 3: Mid-to Long-term Vision
Mid-to Long-term Vision Contribute to improving hospital care quality and efficiency Contribute to drug delivery innovation Shift gears to enhance sales and achieve sustainable growth © Terumo Corporation Dec 12, 2016 2/19
Slide 4: Market Dynamics and Healthcare Needs
Market Dynamics and Healthcare Needs Market Environment Healthcare Needs Increase patient count due to aging society Improve patients QOL Hospital market Japan Healthcare expenditure constraints Deliver care efficiently Increased hospitals purchasing power in developed countries Offer affordable pro
Slide 5: Mid- to Long-term Strategy: General Hospital Company
Mid- to Long-term Strategy: General Hospital Company Establish a Expand the hospital business in healthcare Japan by offering comprehensive platform value Healthcare needs Be the best partner for Deliver new value to expand B2B pharmaceutical business in the global market companies © Terumo Corporat
Slide 6: Mid- to Long-term Strategy: General Hospital Company
Mid- to Long-term Strategy: General Hospital Company Establish a Expand the hospital business in healthcare Japan by offering comprehensive platform value Healthcare needs Be the best partner for Deliver new value to expand B2B pharmaceutical business in the global market companies © Terumo Corporat
Slide 7: Establish a Healthcare Platform
Establish a Healthcare Platform Address hospital needs by delivering comprehensive product offerings Healthcare needs Value to deliver Key products Improve patient Improved safety Advanced infusion system QOL Digital health Deliver care Operational efficiency efficiently Pain management drugs Adhesi
Slide 8: Improve Therapy Safety and Operational Efficiency
Improve Therapy Safety and Operational Efficiency Provide a safer healthcare environment and establish a healthcare platform by connecting products to hospital networks Value to deliver Connecting advanced infusion system and digital health Advanced Closed Database infusion system Injection system f
Slide 9: Achieve Early Discharge and Improved QOL
Achieve Early Discharge and Improved QOL Pain Management Prevent Adhesion Postoperative pain management enables Postoperative adhesion is a major early discharge complication Keys to early discharge: Stomachache, intestinal obstruction, and Food consumption and exercising sterility occurring with 50
Slide 10: Optimize Sales Force to Align with Healthcare Policy
Optimize Sales Force to Align with Healthcare Policy Adapt to the shift from hospital-based to community-based healthcare Past healthcare regime Future healthcare system General ward Approach Short-term Short-term acute care acute care Convalescent care Clinic, Homecare Functional acute care first C
Slide 11: Mid- to Long-term Strategy: General Hospital Company
Mid- to Long-term Strategy: General Hospital Company Establish a Expand the hospital business in healthcare Japan by offering comprehensive platform value Healthcare needs Be the best partner for Deliver new value to expand B2B pharmaceutical business in the global market companies © Terumo Corporat
Slide 12: Be the Best Partner for Pharmaceutical Companies
Be the Best Partner for Pharmaceutical Companies Expand B2B business by matching evolved pharmaceutical companies’ needs Pharmaceutical needs Value to deliver Key products Design a delivery Material technologies for system adapted to biologics Delivery systems for new drugs biologics and vaccines De
Slide 13: Significant Opportunities Arise for Device by Drug Innovation
Significant Opportunities Arise for Device by Drug Innovation Expansion of biologics and immune therapy create new markets for medtech companies Biologics 医療ニーズ Immune therapy Biologics market From tablet to injection Immune therapy (vaccine) +9% p.a. +8% p.a. •Stabilizing the formula •High viscosit
Slide 14: Biologics: Strategic Partnership with Pharmaceutical Companies (Japan)
Biologics: Strategic Partnership with Pharmaceutical Companies (Japan) Provide solutions for biologics to expand the CMO Package business Market Value to deliver CMO: Device and Production expansion Device development Material technologies for biologics Offer comprehensive and production suitabl
Slide 15: Biologics: Enhance Drug Value through Devices
Biologics: Enhance Drug Value through Devices Offer specialized products to expand the business where unmet needs exist Develop devices to be Value to deliver prepackaged with drugs Market expansion Suitable delivery device Strengthen the New disease area for drugs prepackaged business • Inject adeq
Slide 16: Immune Therapy: Generate Markets with New Device
Immune Therapy: Generate Markets with New Device Expand intradermal injection device business with strategic partners in immune therapy market Value to deliver Intradermal injection device Market expansion Increases efficacy of Introduce the device Easy and accurate injection immune effect for seaso
Slide 17: Evolve the Organization to Execute Growth Strategy
Evolve the Organization to Execute Growth Strategy Reorganize into Hospital System and Alliance divisions Current organization New organizational structure General • GHP Hospital Hospital • D&D (excluding B2B) Products Systems • DM and Consumer Healthcare General General Hospital D&D Hospital Compan
Slide 18: Enrich the Product Pipeline around Key Initiatives
Enrich the Product Pipeline around Key Initiatives Long Term Pipeline Mid- term Long- term New products contributing to (FY17-19) (Beyond growth beyondFY20) 2020 • Next generation SmartPump • Access device for infusion Hospital • Vertical Infusion Pump • Pain Management Drugs System • Pain Managemen
Slide 19: Sales and Operating Income Target toward FY21
Sales and Operating Income Target toward FY21 Sales Operating Income* Shift gears to enhance sales Achieve faster profit growth than sales growth through continuous profit management Mid-single-digit High single-digit growth growth Adjusted operating margin improves by 2 - 3% pts Plan FX rate: USD=1
Slide 20: Beyond FY21
Beyond FY21 Hospital Systems Division Alliance Division Achieve stable growth in Japan and Growth driver selective growth in overseas markets • Provide medical devices and services to • Maintain a competitive edge by gaining support community-integrated care systems customer loyalty • Reduce hospita
Slide 21: © Terumo Corporation
“TERUMO © Terumo Corporation
Slide 22: Disclaimer
Disclaimer The information that Terumo discloses and the forward-looking statements including financial projections are based upon our assumptions using information available to us at the time and are not intended to be guarantees of future events or performance. Accordingly, it should be noted that